[Clinical observation of shexiang baoxinwan for treatment of coronary heart disease with angina pectoris].
Two hundred and ten patients with angina pectoris in coronary heart disease were randomly assigned to receiving Shexiang Baoxinwan (SXBXW), the protecting heart musk pills (110 patients), or receiving isosorbide dinitrate (100 patients) for 2 weeks. They were well matched for age, anginal types, complications and cardiac functional grading. The results demonstrated that both agents not only could reduce significantly the frequencies of anginal episodes and the consumption amount of nitroglycerin per day, they also could result in significant improvement of the sigma ST segment depression in electrocardiogram. Furthermore, the SXBXW had better efficacy than that of isosorbide dinitrate in the total improvement rate of symptoms of angina pectoris and of ECG, and in the reduction of incidence of headache, i.e. 90.0% vs. 76.0%; 58.6% vs. 40.8%; 0.9% vs. 17%, respectively (P < 0.05 or P < 0.01). In addition, the onset of action of both agents was rapid, within five minutes (83.4% in patients using SXBXW vs. 86.3% in control group, P > 0.05).
Huashan Hospital, Shanghai Medical University.
S Y
SY
Wang
R H
RH
Dai
C
C
Jin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000188:drug therapy*; D016022:Case-Control Studies; D003327:Coronary Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D008419:Materia Medica / Q000627:therapeutic use*; D008875:Middle Aged; D014665:Vasodilator Agents / Q000627:therapeutic use*
D008419:Materia Medica; D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate